Plant-derived H7 VLP vaccine elicits protective immune response against H7N9 influenza virus in mice and ferrets

Vaccine

Volumn 33, Issue 46, 2015, Pages 6282-6289

  Pillet, S ^a,b   Racine, T ^c   Nfon, C ^d   Di Lenardo, T Z ^b   Babiuk, S ^d,e   Ward, B J ^a   Kobinger, G P ^c,e,f   Landry, N ^a  

^a Medicago Inc   (Canada)

^b RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^d CANADIAN FOOD INSPECTION AGENCY   (Canada)

^e UNIVERSITY OF MANITOBA   (Canada)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Ferrets; H7N9; Immunogenicity; Influenza A; Mice; NICOTIANA benthamiana; Plant made vaccine; Virus like particle

Indexed keywords

ALUMINUM POTASSIUM SULFATE; H7 VIRUS LIKE PARTICLE VACCINE; HEMAGGLUTININ; INFLUENZA VACCINE; PLACEBO; UNCLASSIFIED DRUG; VIRUS LIKE PARTICLE VACCINE; HEMAGGLUTININ, AVIAN INFLUENZA A VIRUS; IMMUNOLOGICAL ADJUVANT; INFLUENZA VIRUS HEMAGGLUTININ; RECOMBINANT PROTEIN; VIRUS ANTIBODY;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; ASYMPTOMATIC INFECTION; CD3+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; FERRET; IMMUNE RESPONSE; IMMUNOGENICITY; INFANT; INFLUENZA A; INFLUENZA A VIRUS (A/ANHUI/1/2013(H7N9)); INFLUENZA A VIRUS (A/HANGZHOU/1/2013(H7N9)); INFLUENZA A VIRUS (H7N9); MALE; MOUSE; NONHUMAN; PANDEMIC; PRIORITY JOURNAL; SINGLE DRUG DOSE; VACCINATION; VIRUS LOAD; WEIGHT REDUCTION; ANIMAL; BAGG ALBINO MOUSE; BLOOD; BODY WEIGHT; DISEASE MODEL; GENETICS; IMMUNIZATION; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; LUNG; NOSE CAVITY; ORTHOMYXOVIRIDAE INFECTIONS; PATHOLOGY; SURVIVAL ANALYSIS; TOBACCO; TRANSGENIC PLANT; VIROLOGY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; BODY WEIGHT; DISEASE MODELS, ANIMAL; FEMALE; FERRETS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; IMMUNIZATION SCHEDULE; INFLUENZA A VIRUS, H7N9 SUBTYPE; INFLUENZA VACCINES; INJECTIONS, INTRAMUSCULAR; LUNG; MALE; MICE, INBRED BALB C; NASAL CAVITY; ORTHOMYXOVIRIDAE INFECTIONS; PLACEBOS; PLANTS, GENETICALLY MODIFIED; RECOMBINANT PROTEINS; SURVIVAL ANALYSIS; TOBACCO; VACCINES, VIRUS-LIKE PARTICLE; VIRAL LOAD;

EID: 84946615903     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.09.065     Document Type: Article

References (46)

1. WHO. WHO RISK ASSESSMENT Human Infections with avian influenza A(H7N9) virus. 2014; Available from: http://www.who.int/influenza/human_animal_interface/influenza_h7n9/riskassessment_h7n9_2Oct14.pdf?ua=1.
2. Gao H.N., et al. Clinical findings in 111 cases of influenza A (H7N9) virus infection. N Engl J Med 2013, 368(24):2277-2285.
3. Qi X., et al. Probable person to person transmission of novel avian influenza A (H7N9) virus in Eastern China, 2013: epidemiological investigation. BMJ 2013, 347:f4752.
4. Xiong X., et al. Receptor binding by an H7N9 influenza virus from humans. Nature 2013, 499(7459):496-499.
5. Ramos I., et al. H7N9 influenza viruses interact preferentially with alpha2,3-linked sialic acids and bind weakly to alpha2,6-linked sialic acids. J Gen Virol 2013, 94(Pt 11):2417-2423.
6. Zhang Q., et al. H7N9 influenza viruses are transmissible in ferrets by respiratory droplet. Science 2013, 341(6144):410-414.
7. Belser J.A., Katz J.M., Tumpey T.M. The ferret as a model organism to study influenza A virus infection. Dis Model Mech 2011, 4(5):575-579.
8. Pandey A., et al. Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses. Hum Vaccine 2010, 6(2).
9. Skowronski D.M., et al. Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. PLoS One 2014, 9(3):e92153.
10. Kang S.M., et al. Influenza vaccines based on virus-like particles. Virus Res 2009, 143(2):140-146.
11. Scotti N., Rybicki E.P. Virus-like particles produced in plants as potential vaccines. Exp Rev Vaccines 2013, 12(2):211-224.
12. Pyo H.M., et al. Pandemic H1N1 influenza virus-like particles are immunogenic and provide protective immunity to pigs. Vaccine 2012, 30(7):1297-1304.
13. D'Aoust M.A., et al. The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza. Plant Biotechnol J 2010, 8(5):607-619.
14. D'Aoust M.A., et al. Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice. Plant Biotechnol J 2008, 6(9):930-940.
15. globalbiodefense. Available from: http://globalbiodefense.com/2012/07/28/darpa-program-hits-milestone-in-plant-based-vaccines-for-pandemics/.
16. Landry N., et al. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS One 2010, 5(12):e15559.
17. WHO Manual on animal influenza diagnosis and surveillance 2002.
18. Pillet S., von Messling V. Canine distemper virus selectively inhibits apoptosis progression in infected immune cells. J Virol 2009, 83(12):6279-6287.
19. Weingartl H.M., et al. Experimental infection of pigs with the human 1918 pandemic influenza virus. J Virol 2009, 83(9):4287-4296.
20. Couch R.B., et al. A randomized clinical trial of an inactivated avian influenza A (H7N7) vaccine. PLoS One 2012, 7(12):e49704.
21. Cox R.J., et al. A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine. Vaccine 2009, 27(13):1889-1897.
22. Mallett C.P., et al. AS03-adjuvanted H7N1 detergent-split virion vaccine is highly immunogenic in unprimed mice and induces cross-reactive antibodies to emerged H7N9 and additional H7 subtypes. Vaccine 2015, 33(32):3784-3787.
23. Mulligan M.J., et al. Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial. JAMA 2014, 312(14):1409-1419.
24. Smith G.E., et al. Development of influenza H7N9 virus like particle (VLP) vaccine: Homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus. Vaccine 2013, 31(40):4305-4313.
25. Pushko P., et al. Recombinant H7 hemagglutinin forms subviral particles that protect mice and ferrets from challenge with H7N9 influenza virus. Vaccine 2015, 33(38):4975-4982.
26. Darveau R.P., Chilton P.M. Naturally occurring low biological reactivity lipopolysaccharides as vaccine adjuvants. Expert Rev Vaccines 2013, 12(7):707-709.
27. Klausberger M., et al. One-shot vaccination with an insect cell-derived low-dose influenza A H7 virus-like particle preparation protects mice against H7N9 challenge. Vaccine 2014, 32(3):355-362.
28. Maher J.A., DeStefano J. The ferret: an animal model to study influenza virus. Lab Anim (NY) 2004, 33(9):50-53.
29. Xu L., et al. The mouse and ferret models for studying the novel avian-origin human influenza A (H7N9) virus. Virol J 2013, 10:253.
30. van der Laan J.W., et al. Animal models in influenza vaccine testing. Expert Rev Vaccines 2008, 7(6):783-793.
31. Baras B., et al. Pandemic H1N1 vaccine requires the use of an adjuvant to protect against challenge in naive ferrets. Vaccine 2011, 29(11):2120-2126.
32. Clegg C.H., et al. Adjuvant solution for pandemic influenza vaccine production. Proc Natl Acad Sci USA 2012, 109(43):17585-17590.
33. Yan J., et al. Protective immunity to H7N9 influenza viruses elicited by synthetic DNA vaccine. Vaccine 2014.
34. McKinstry K.K., et al. Memory CD4T cell-mediated immunity against influenza A virus: more than a little helpful. Arch Immunol Ther Exp (Warsz) 2013, 61(5):341-353.
35. Sant A.J., et al. Immunodominance in CD4 T-cell responses: implications for immune responses to influenza virus and for vaccine design. Expert Rev Vaccines 2007, 6(3):357-368.
36. Schotsaert M., Saelens X., Leroux-Roels G. Influenza vaccines: T-cell responses deserve more attention. Expert Rev Vaccines 2012, 11(8):949-962.
37. De Groot A.S., et al. Low immunogenicity predicted for emerging avian-origin H7N9: implication for influenza vaccine design. Hum Vaccin Immunother 2013, 9(5):950-956.
38. Day C.L., et al. Proliferative capacity of epitope-specific CD8 T-cell responses is inversely related to viral load in chronic human immunodeficiency virus type 1 infection. J Virol 2007, 81(1):434-438.
39. Lin J., et al. Lung homing CTLs and their proliferation ability are important correlates of vaccine protection against influenza. Vaccine 2010, 28(35):5669-5675.
40. Pillet S., et al. Cellular immune response in the presence of protective antibody levels correlates with protection against 1918 influenza in ferrets. Vaccine 2011, 29(39):6793-6801.
41. McMichael A.J., et al. Cytotoxic T-cell immunity to influenza. N Engl J Med 1983, 309(1):13-17.
42. Dienz O., et al. The induction of antibody production by IL-6 is indirectly mediated by IL-21 produced by CD4+ T cells. J Exp Med 2009, 206(1):69-78.
43. Castellino F., Germain R.N. Cooperation between CD4+ and CD8+ T cells: when, where, and how. Annu Rev Immunol 2006, 24:519-540.
44. Laidlaw B.J., et al. CD4(+) T cell help guides formation of CD103(+) lung-resident memory CD8(+) T cells during influenza viral infection. Immunity 2014, 41(4):633-645.
45. Landry N., et al. Influenza virus-like particle vaccines made in Nicotiana benthamiana elicit durable: poly-functional and cross-reactive T cell responses to influenza HA antigens. Clin Immunol 2014, 154(2):164-177.
46. Meunier I., et al. Influenza pathogenesis: lessons learned from animal studies with H5N1, H1N1 Spanish, and pandemic H1N1 2009 influenza. Crit Care Med 2010, 38(4 Suppl):e21-e29.